Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | HTR2A | P28223 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 4/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | HTR7 | P34969 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503278 | 1.00 | HTR1A (0.57) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL24228045 | 0.99 | HTR1A (0.58) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL30503247 | 0.99 | HTR1A (0.58) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL26192298 | 0.90 | HTR1A (0.58) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL30503331 | 0.89 | MAOB (0.53) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL24227991 | 0.89 | MAOB (0.53) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL30503309 | 0.88 | MAOB (0.52) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL24228066 | 0.88 | MAOB (0.52) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL24227986 | 0.86 | HTR2A (0.52) | HTR1AHTR2ADRD3DRD2HTR7 | |
| SCHEMBL30503264 | 0.86 | HTR2A (0.52) | HTR1AHTR2ADRD3DRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-08-31 | — | — | US | disclosed |
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-08-31 | — | — | US | disclosed |
| CN-116472267-A | Butyrylcholinesterase reactivating agent | 法兰西国由中央军队卫生服务局代表 | 2023-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270750-A1 | CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS | BCHE, ACHE, CHAT | HTR1A 2783/4885HTR2A 3036/4885DRD3 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.